Skip NavigationSkip to Content
Return Return to Search Results

Novel Dithiolethione-Modified Nonsteroidal Anti-Inflammatory Drugs in Human Hepatoma HepG2 and Colon LS180 Cells

  1. Author:
    Bass, S. E.
    Sienkiewicz, P.
    MacDonald, C. J.
    Cheng, R.
    Sparatore, A.
    Del Soldato, P.
    Roberts, D. D.
    Moody, T. W.
    Wink, D. A.
    Yeh, G. C.

  2. Author Address

    Sienkiewicz, Pawel, MacDonald, Christopher J.; Cheng, Robert Y. S.; Yeh, Grace Chao] NCI, Lab Metab, Frederick, MD 21701 USA. [Sparatore, Anna] Univ Milan, Ist Chim Farmaceut, I-20122 Milan, Italy. [Del Soldato, Piero] Sulfidris, Milan, Italy. [Wink, David A.] NCI, Ctr Canc Res, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA. [Roberts, David D.] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA. [Moody, Terry W.] NCI, Off Director, NIH, Bethesda, MD 20892 USA.
    1. Year: 2009
  2. Journal: Clinical Cancer Research
    1. 15
    2. 6
    3. Pages: 1964-1972
  4. Type of Article: Article
  1. Abstract:

    Purpose: Nonsteroidal anti-inflammatory drugs (NSAID) are promising chemopreventive agents against colon and other cancers. However, the molecular basis mediated by NSAIDs for chemoprevention has not been fully elucidated. Environmental carcinogens induce DNA mutation and cellular transformation, therefore, we examined the effect of NSAIDs on carcinogenesis mediated by the aryl hydrocarbon receptor signaling pathway. In this study, we investigated the activities of a new class of NSAIDs containing dithiolethione moieties (S-NSAID) on both arms of carcinogenesis. Experimental Design: We investigated the effects of the S-NSAIDs, S-diclofenac and S-sulindac, on carcinogen activation and detoxification mechanisms in human hepatoma HepG2 and human colonic adenocarcinoma LS180 cells. Results: We found that S-diclofenac and S-sulindac inhibited the activity and expression of the carcinogen activating enzymes, cytochromes P-450 (CYP) CYP1A1, CYP1B1, and CYP1A2. Inhibition was mediated by transcriptional regulation of the aryl hydrocarbon receptor (AhR) pathway. The S-NSAIDs down-regulated carcinogen-induced expression of CYP1A1 heterogeneous nuclear RNA, a measure of transcription rate. Both compounds blocked carcinogen-activated AhR from binding to the xenobiotic responsive element as shown by chromatin immunoprecipitation. S-diclofenac and S-sulindac inhibited carcinogen-induced CYP enzyme activity through direct inhibition as well as through decreased transcriptional activation of the AhR. S-sulindac induced expression of several carcinogen detoxification enzymes of the glutathione cycle including glutathione S-transferase A2, glutamate cysteine ligase catalytic subunit, glutamate cysteine ligase modifier subunit, and glutathione reductase. Conclusions: These results indicate that S-diclofenac and S-sulindac may serve as effective chemoprevention agents by favorably balancing the equation of carcinogen activation and detoxification mechanisms.

    See More

  1. Keywords:

External Sources

  1. PMID: 19276279

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel